Table 3 Prevalence of malaria according to selected risk factors among HIV infected pregnant women receiving co-trimoxazole (N = 420)

WHO clinical stage

Stage I

338

12 (3.6)

1

Stage II

43

2 (4.7)

0.851

0.171-4.226

0.844

Stage III-IV

39

5 (12.8)

0.031^a

2.305

0.699-7.597

0.170

CD4 count (cells/μL)*

≥500

104

4 (3.8)

-

350-499

85

3 (3.5)

-

200-349

96

8 (8.3)

⁻

<200

59

4 (6.8)

0.417^a

-

Pregnancy trimester

1st trimester

20

1 (5)

-

2nd trimester

206

9 (4.4)

-

3rd trimester

194

9 (4.6)

0.986^a

-

Gravidity

Primigravidae

139

6 (4.3)

-

Secundigravidae

148

5 (3.4)

-

Multigravidae

133

8 (6)

0.563^a

-

Adherence to co-trimoxazole

Good

208

2 (1)

1

Average

80

4 (5)

3.578

0.611-20.955

0.157

Poor

132

13 (9.8)

0.001^a

6.806

1.346-34.429

0.02

ITN use

Yes

380

15 (3.9)

-

No

40

4 (10)

0.096^b

-

ART use category

Prophylaxis

288

11 (3.8)

-

Life long

132

8 (6.1)

0.305^a

-